A regulatory science perspective on warfarin therapy: A pharmacogenetic opportunity

Journal of Clinical Pharmacology

Volumn 49, Issue 2, 2009, Pages 138-146

  Kim, Myong Jin ^a   Huang, Shiew Mei ^a   Meyer, Urs A ^a   Rahman, Atiqur ^a   Lesko, Lawrence J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

CYP2C9; Pharmacogenetics; VKORC1; Warfarin

Indexed keywords

ABACAVIR; ATOMOXETINE; AZATHIOPRINE; CARBAMAZEPINE; CODEINE; CYTOCHROME P450 2C9; DRUG METABOLIZING ENZYME; ERLOTINIB; IRINOTECAN; MARAVIROC; MERCAPTOPURINE; TETRABENAZINE; THIORIDAZINE; TRASTUZUMAB; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ADVISORY COMMITTEE; AGE; ANTICOAGULANT THERAPY; BLEEDING; BODY WEIGHT; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DOSE CALCULATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ENVIRONMENTAL FACTOR; ETHNICITY; FOOD AND DRUG ADMINISTRATION; GENDER; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HEART ATRIUM FIBRILLATION; HEREDITY; HOSPITALIZATION; HUMAN; INDIVIDUALIZATION; INTERNATIONAL NORMALIZED RATIO; MORTALITY; MULTIPLE LINEAR REGRESSION ANALYSIS; PHARMACOGENETICS; PROTHROMBIN TIME; REVIEW; SMOKING; THROMBOEMBOLISM; WILD TYPE;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WARFARIN;

EID: 58849142451     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008328098     Document Type: Review

References (51)

1. Coumadin [product label]. http://www.fda.gov/cder/foi/label/2007/ 009218s105lblv2[1].pdf. Accessed on May 25, 2008.
2. Aquilante CL, Langaee TY, Lopez LM, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther. 2006 ; 79: 291-302.
3. Lal S., Jada SR, Xiang X., Lim WT, Lee EJ, Chowbay B. Pharmacogenetics of target genes across the warfarin pharmacological pathway. Clin Pharmacokinet. 2006 ; 45: 1189-1200.
4. Reynolds KK, Valdes R. Jr, Hartung BR, Linder MW Individualizing warfarin therapy. Personalized Medicine. 2007 ; 4: 11-31.
5. U.S. FDA. Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science 2005, Warfarin. http://www.fda.gov/ohrms/dockets/ac/ cder05.html#PharmScience. Accessed on May 25, 2008.
6. McWilliam A., Lutter R., Nardinelli C. Health Care Savings From Personalizing Medicine Using Genetic Testing: The Case of Warfarin. Washington, DC: AEI-Brookings Joint Center for Regulatory Studies ; 2006. http://aei-brookings.org/admin/authorpdfs/redirect-safely.php?fname=../pdffiles/ WP06-23-topost.pdf
7. IMS Health National Prescription Audit PLUS TM Data. Extracted September 2005.
8. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006 ; 296: 1858-1866.
9. Wysowski DK, Nourjah P., Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007 ; 167: 1414-1419.
10. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994 ; 4: 39-42.
11. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002 ; 287: 1690-1698.
12. Sanderson S., Emery J., Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med. 2005: 7: 97-104.
13. D'Andrea G., D'Ambrosio RL, Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005 ; 105: 645-649.
14. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005 ; 352: 2285-2293.
15. Hylek EM Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors. Semin Vasc Med. 2003 ; 3: 271-278.
16. Garcia DA, Regan S., Crowther M., Hylek EM The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol. 2006 ; 47: 804-808.
17. Fang MC, Chang Y., Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004 ; 141: 745-752.
18. Herman D., Peternel P., Stegnar M., Breskvar K., Dolzan V. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost. 2006 ; 95: 782-787.
19. McCormick D., Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med. 2001 ; 161: 2458-2463.
20. Matchar DB, Samsa GP, Cohen SJ, Oddone EZ, Jurgelski AE Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the Managing Anticoagulation Services Trial. Am J Med. 2002 ; 113: 42-51.
21. AstraZeneca, Exanta trial data. http://www.astrazeneca.se/download/2003/ 2003Cameron.pdf.
22. Aithal GP, Day CP, Kesteven PJ, Daly AK Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999 ; 353: 717-719.
23. Au N., Rettie AE, Pharmacogenomics of 4-hydoxy coumarin anticoagulation. Drug Metab Rev. 2008 ; 40 ; 355-375.
24. Kamali F., Khan TI, King BP, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin, Clin Pharmacol Ther. 2004 ; 75: 204-212.
25. Herman D., Locatelli I., Grabnar I., et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 2005 ; 5: 193-202.
26. Bloch A., Ben-Chetrit E., Muszkat M., Caraco Y. Major bleeding caused by warfarin in a genetically susceptible patient. Pharmacother. 2002 ; 22: 97-101.
27. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005 ; 106: 2329-2333.
28. Gage B., Eby C., Johnson JA, et al, Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008 ;84: 326-331.
29. Schelleman H., Chen J., Chen Z., et al. Dosing algorithms to predict warfarin maintenance dose in caucasians and African Americans. Clin Pharmacol Ther. 2008 ; 84: 332-339.
30. Wen WS, Lee MTM, Chen J-J., et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther. 2008 ; 84: 83-89.
31. Wadelius M., Chen LY, Downes K., et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005 ; 5: 262-270.
32. McClain MR, Palomaki GE, Piper M., Haddow JE A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med. 2008 ; 10: 89-98.
33. Lee JY, Madabushi R., Lesko LJ, et al. Leveraging prior quantitative knowledge demonstrates the importance of genotype-based dosing of warfarin. Paper presented at: American Conference on Pharmacometrics, March 2008, Tuscon, Arizona.
34. Gage BF, Lesko LJ Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis. 2008 ; 25: 45-51.
35. Epstein RS Warfarin and beyond-how pharmacy benefit managers (PBMs) view pharmacogenomics and prescription medicine. Paper presented at: DIA workshop ; December 11, 2007 ; Bethesda, Md.
36. Caraco Y., Blotnick S., Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2008 ; 83: 460-470.
37. Lesko LJ The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin Pharmacol Ther. 2008 ; 84: 301-303.
38. Garcia DA Warfarin and pharmacogenomic testing: the case for restraint. Clin Pharmacol Ther. 2008 ; 84: 303-305.
39. Is warfarin pharmacogenomic testing ready for prime time? Debate at American Association of Clinical Chemistry meeting ; July 22, 2008 ; Washington DC. http://www.aacc.org/publications/cln/2008/July/dailies/Pages/mon-daily1. aspx.
40. Huang S-M. Warfarin pharmacogenetic testing is now ready for prime time. Presentation at warfarin pharmacogenetics debate, American Association of Clinical Chemistry meeting ; July 28, 2008 ; Washington, DC. http://www.fda.gov/cder/genomics/presentations.htm.
41. Ansell J., Hirsh J., Hylek E., et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. 8 th ed. Chest. 2008 ; 133 (6 suppl). 160S - 198S.
42. McWilliam A., Lutter R., Nardinelli C. Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin. Personalized Medicine. 2008 ; 5: 279-284.
43. Huang S. -M, Temple R. Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther. 2008 ; 84: 287-294.
44. Tham LS, Goh BC, Nafziger A., et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther. 2006 ; 80: 346-355.
45. Kimura R., Miyashita K., Kokubo Y., et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 2007 ; 120: 181-186.
46. Shikata E., Ieiri I., Ishiguro S., et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood. 2004 ; 103: 2630-2635.
47. Zhu Y., Shennan M., Reynolds KK, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem. 2007 ; 53: 1199-1205.
48. Millican EA, Lenzini PA, Miligan PE, et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood. 2007 ; 110: 1511-1515.
49. Takahashi H., Kashima T., Nomoto S., et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 1998 ; 8: 365-373.
50. Voora D., Eby C., Linder MW, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 2005 ; 93: 700-705.
51. Andersson T., Flockhart DA, Goldstein DB, et al. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic test. Clin Pharmacol Ther. 2005 ; 78: 559-581.